Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind trial of aprepitant for prevention of chemotherapy-induced nausea and vomiting in pediatric patients
KCT0000301Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Merck & Co. Started Nov 2011; status: recruiting.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on KCT0000301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000301.